Eli Lilly Diabetes Market Share | Global Positioning, Product Insights & Forecast 2025

Q: What is the current and projected market size of Eli Lilly’s diabetes segment?

The market size is currently USD 20.5 billion and is projected to reach USD 40.2 billion by 2032.

Q: What are the major growth factors driving the Eli Lilly diabetes market?

Key factors include the rising global diabetes burden, innovation in insulin and GLP-1 therapies, and expanded access in emerging markets.

Q: How is technology impacting growth in Eli Lilly’s diabetes market?

Advancements in digital health tools, connected insulin pens, and AI-based research are significantly contributing to growth.

Q: What is the compound annual growth rate (CAGR) of the Eli Lilly diabetes market?

The Eli Lilly diabetes market is expected to grow at a CAGR of 8.7% from 2024 to 2032.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA4380

Publication Date: Jun 2025

What is the size of Eli Lilly diabetes market?

According to 6Wresearch internal database and industry insights, the size of Eli lily diabetes market was demonstrated around USD 20.5 billion in 2024 and is projected to reach USD 40.2 billion by 2031, growing at a steady CAGR of 8.7% from 2025 to 2031.

Eli Lilly has made significant strides in the diabetes care arena, leveraging a solid product pipeline, increasing access to insulin therapies, and growing worldwide awareness of diabetes management. ELI's innovation-focused approach to GLP-1 receptor agonists and continued investment within the insulin delivery technology space, in addition to creative partnerships with new market entrants, will continue to stimulate market growth. The new diabetes drugs will allow for more individualized and effective treatment options, lead to improved patient outcomes across different populations.

Major Growth Factors of the Eli Lilly diabetes market

Advancements in insulin delivery technology
Rising global prevalence of diabetes
Growing adoption of digital diabetes management tools
Expansion in emerging markets
Focus on patient affordability programs
Collaborations with health tech companies
Regulatory approvals of new diabetes drugs
Increased healthcare expenditure

Eli Lilly diabetes market Trends

The Eli Lilly diabetes market is beginning to move towards integrated diabetes care solutions, including digital health platforms and connected devices. There appears to be a shift towards personalized treatment regimens and the development of long-acting insulin analogues. Eli Lilly is also applying artificial intelligenc oriented research and using real-world evidence to better treatment practices and improve patient engagement. All of these features are attempting to streamline disease management and reduce the burden on healthcare systems while providing patients with more control.

Emerging Developments in the Eli Lilly diabetes market

Recent developments in Eli lily diabetes market include the release of biosimilar insulin products, advancements in once-weekly insulin products, and collaboration efforts to improve digital diabetes care platforms. The company is also increasing manufacturing capacity to respond to increased global demand. These developments are meant to improve patient treatment affordability and availability in every region of the world. In the same vein, Eli Lilly, with its focus on scalable production and global distribution, is poised to meet the needs of emerging markets and underserved individuals.